行情

TRVN

TRVN

Trevena
NASDAQ

实时行情|Nasdaq Last Sale

0.9736
+0.0694
+7.68%
盘后: 0.9800 +0.0064 +0.66% 17:54 01/24 EST
开盘
0.9100
昨收
0.9042
最高
0.9875
最低
0.9100
成交量
187.88万
成交额
--
52周最高
2.000
52周最低
0.5050
市值
9,014.88万
市盈率(TTM)
-3.2638
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

TRVN 新闻

  • How Much Are Trevena, Inc. (NASDAQ:TRVN) Insiders Spending On Buying Shares?
  • Simply Wall St..01/17 16:56
  • Is Trevena Inc (TRVN) Going To Burn These Hedge Funds?
  • Insider Monkey.2019/12/23 19:55
  • Trevena Announces Initiation of Proof-of-Concept Study for TRV734 for Potential Treatment of Opioid Use Disorder
  • GlobeNewswire.2019/12/23 12:00
  • Trevena Highlights Presentation Of Phase 1 Data On TRV250 For Acute Migraine At American College of Neuropsychopharmacology 2019 Annual Meeting
  • Benzinga.2019/12/12 12:23

更多

所属板块

生物技术和医学研究
-2.64%
制药与医学研究
-2.00%

热门股票

名称
价格
涨跌幅

TRVN 简况

Trevena Inc. is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers. It is also developing TRV250, a G protein biased ligand targeting the o-receptor, as a compound with a non-narcotic mechanism for the treatment of migraine. TRV250 also may have utility in a range of other central nervous system (CNS) indications. It is focused on commencing a Phase I study of TRV250 in the United Kingdom. Its ABLE product platform is a collection of biological information, in vitro assays, know-how and expertise that it uses to identify unique G protein coupled receptors (GPCR)-targeted biased ligands with various pharmaceutical properties.
展开

Webull提供Trevena Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。